Primary source: Inspections and Compliance
The Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System was authorized by the FDA effective August 25, 2026.
This device is the first in the world to continuously monitor both glucose and ketone levels, providing crucial data for managing diabetes and preventing critical complications such as diabetic ketoacidosis.
Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
The FDA has granted marketing authorization for the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, a wearable device that allows individuals aged 2 years and older with diabetes to monitor both blood sugar and ketone levels simultaneously. This device continuously checks these levels every minute and sends real-time alerts to users, enhancing early detection of diabetic ketoacidosis.
What changed: The Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System was authorized by the FDA effective August 25, 2026.
Why it matters: This device is the first in the world to continuously monitor both glucose and ketone levels, providing crucial data for managing diabetes and preventing critical complications such as diabetic ketoacidosis.
Practical implication: Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.
Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.
Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.
Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.
